Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLS101 in Premenstrual Dysphoric Disorder (PMDD)
NCT07818720Phase 1Not yet recruiting
- Sponsor
- MycoMedica Life Sciences
- Start
- Dec 2026
- Primary completion
- Sep 2027
01
Overview
Phase 1, randomised trial of lorundrostat in Premenstrual Dysphoric Disorder (PMDD) (4 arms), sponsored by MycoMedica Life Sciences. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v6.0 at 11 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
lorundrostat
03
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Beyond the preview
Go deeper on NCT07818720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818720.